PARKINSONS DISEASE THERAPEUTICS MARKET ANALYSIS

Parkinsons Disease Therapeutics Market, By Drug Class (Levodopa, Dopamine agonists, MAO-B inhibitors, Anticholinergics, Others (Catechol-O-methyl transferase [COMT] inhibitors and amantadine, among Others)), By Route of Administration (Oral, Injectable, Nasal, Transdermal, Others (Rectal, Sublingual, among Others)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Oct 2023
Code : CMI494
Pages :312
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Parkinsons Disease Therapeutics Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global Parkinsons disease therapeutics market over the forecast period. North America is estimated to hold 33.5% of the market share in 2022 The global Parkinsons disease therapeutics market is expected to witness significant growth in the coming years, driven by the increasing research and development activities for the production of parkinson’s disease drugs by market players in the region. For instance, in 2022, Denali Therapeutics Inc., a clinical-stage biopharmaceutical company, and Biogen Inc., a global biotechnology company, a uniquely different pharmaceutical company are conducting a clinical trial to evaluate the efficacy and safety of BIIB122 (DNL151), as compared to placebo in approximately 640 participants with early-stage Parkinson’s disease. Biogen announced the initiation of dosing among the participants. The study is in Phase II, and the study is estimated to be completed by August 2025.